Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Fungal infection

Fungal infection

Subtypes of Fungal infection

Coccidioidomycosis 7 Blastomycosis 3 Histoplasmosis 3 Mucormycosis 3 Invasive candidiasis 2 Valley Fever 2 Vulvovaginal candidiasis 2 Aspergillosis 1 Mucorales infection 1 Mycetoma 1

28 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Fungal infection

29 trials tracked for Fungal infection: 16 in phase 3 or 4 and 5 with published results. The most-cited published study has 291 citations.

29Trials tracked
16Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 4 Phase 3 12 Phase 2 4 Phase 1 6 Other / NA 3
  1. Phase 3 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Completed · 291 cited
  2. Phase 3 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed · 108 cited
  3. Phase 3 Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Completed · 42 cited
  4. Phase 3 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole Completed · 38 cited
  5. Phase 3 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Completed · 20 cited
  6. Phase 4 A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed
Show 23 more trials
  1. Phase 4 Itraconazole Oral Absorption Completed
  2. Phase 4 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed
  3. Phase 4 Effect of Weight and/or Obesity on Caspofungin Drug Concentrations Completed
  4. Phase 3 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed
  5. Phase 3 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Completed
  6. Phase 3 A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066) Completed
  7. Phase 3 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) Completed
  8. Phase 3 Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis Completed
  9. Phase 3 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed
  10. Phase 3 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) Completed
  11. Phase 2 Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Completed
  12. Phase 2 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Completed
  13. Phase 2 Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Completed
  14. Phase 2 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options Completed
  15. Phase 1 Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615) Completed
  16. Phase 1 Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Completed
  17. Phase 1 Anidulafungin PK in Infants and Toddlers Completed
  18. Phase 1 Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) Completed
  19. Phase 1 Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers Completed
  20. Phase 1 Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520) Completed
  21. N/A A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation Completed
  22. N/A Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection Completed
  23. N/A Vfend Special Investigation For Prophylaxis Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Fungal infection: what the trials found

Several trials evaluated the efficacy and safety of various antifungal agents for fungal infections. Posaconazole was studied in multiple trials, demonstrating significant outcomes in mortality rates (p=<.0001) in one large study 5 and clinical responses at 4, 8, and 12 weeks in another 16. Other studies confirmed the use of Posaconazole across various phases [12, 17, 20].

Caspofungin acetate was evaluated in multiple trials [3, 8, 13, 14]. One study specifically noted a lower percentage of patients with proven or probable invasive fungal infections (3.1% vs 7.2%) and invasive aspergillosis (0.5% vs 3.1%) in the treatment arm 6.

Other established interventions include fast itraconazole tablets 1, prospective TDM arms 2, SUBA itraconazole, which showed fewer treatment-related adverse events and shorter hospitalizations compared to a comparator 7, Rezafungin for injection 9, isavuconazole 11, and Voriconazole 15.

A study on levofloxacin in a related context showed lower rates of bacteremia (21.9% vs 43.4%) and fever/febrile neutropenia compared to specific control groups 10.

Recent results — preliminary, needs further review

  • Olorofim was evaluated in a Phase 2 trial 18.
  • CD101 was evaluated in a Phase 2 trial 19.
  • Vorico Injection (Voriconazole) was evaluated in a Phase 1 trial 21.

For the clinician treating this condition

  • Posaconazole demonstrated significant mortality reduction (p=<.0001) and measurable clinical responses over a 12-week period.
  • Caspofungin acetate was associated with lower rates of invasive fungal infections and invasive aspergillosis in specific cohorts.
  • SUBA itraconazole showed a favorable safety profile with fewer treatment-related adverse events and shorter hospitalizations compared to alternatives.

AI synthesis of 13 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Coccidioidomycosis outbreak reported among wildland firefighters in California
Infectious Disease
Coccidioidomycosis outbreak reported among wildland firefighters in California Did fighting California wildfires expose firefighters to Valley Fever?
An outbreak investigation report describes a coccidioidomycosis outbreak among wildland firefighters in California.
A 2021 California wildfire outbreak confirmed Valley Fever in firefighters, adding a hidden dust threat to the flames they fight.
CDC Apr 5, 2026
Observational report notes regional increases in Valley fever incidence in Arizona
Infectious Disease
Observational report notes regional increases in Valley fever incidence in Arizona Valley fever cases increased in Arizona over nearly two decades, report finds
An observational report from Arizona describes regional increases in Valley fever incidence during 2005-2022.
Valley fever cases rose in some Arizona regions between 2005 and 2022, according to a new report tracking the fungal infection over nearly t…
CDC Apr 4, 2026
Cave visit linked to suspected histoplasmosis cluster in 12 family travelers from Costa Rica
Infectious Disease
Cave visit linked to suspected histoplasmosis cluster in 12 family travelers from Costa Rica Did a family cave trip lead to a cluster of suspected fungal infections?
A case series describes 12 members of an extended family with suspected histoplasmosis after visiting Venado Caves in Costa Rica.
Twelve family members visited Costa Rican caves and later developed suspected fungal infections, showing how a single trip could link a grou…
CDC Apr 4, 2026
Surveillance report examines fungal infection trends in US during COVID-19 pandemic
Infectious Disease
Surveillance report examines fungal infection trends in US during COVID-19 pandemic Did the pandemic change patterns of serious fungal infections in the US?
A US surveillance report examined trends in coccidioidomycosis, histoplasmosis, and blastomycosis cases from 2019 to 2021 during the COVID-1…
A new report tracked three serious fungal lung infections across the US from 2019 to 2021 to see if the pandemic changed their patterns.
CDC Apr 4, 2026

Questions about Fungal infection

Does having a fungal infection mean I have a bacterial infection in my lungs?

Having a fungal infection in your lungs does not automatically mean you have a bacterial infection, though both can occur together in certain conditions like HIV or COPD.

Full answer →